Mogamulizumab, a monoclonal antibody against C-C chemokine receptor 4 (CCR4), is a second agent approved by the US FDA and European Union for the treatment of MF/SS after at least one prior therapy. This evidence concerns the gene CCR4 and mycosis fungoides.